Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics

Trial Identifier: D3250C00059
Sponsor: AstraZeneca
NCTID:: NCT03953300
Start Date: October 2019
Primary Completion Date: September 2025
Study Completion Date: September 2025
Condition: Asthma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CA, AB Calgary, AB, CA, T2N 4Z6
CA, AB Edmonton, AB, CA, T6G 2G3
CA, ON Hamilton, ON, CA, L8N 4A6
DK Aarhus N, DK, 8200
DK Ålborg, DK, 9000
DK Hvidovre, DK, 2650
DK København NV, DK, 2400
DK Naestved, DK, 4700
DK Odense C, DK, 5000
DK Vejle, DK, 7100
GB Cambridge, GB, CB2 2QQ
GB Headington, GB, OX3 9DU
GB Liverpool, GB, L7 8XP
GB London, GB, W1G 8HU
GB Wythenshawe, GB, M23 9LT
SE Göteborg, SE, 413 45
SE Lund, SE, 221 85
US, CA Los Angeles, CA, US, 90033
US, CT New Haven, CT, US, 06510
US, GA Decatur, GA, US, 30033
US, IA Iowa City, IA, US, 52242
US, KS Kansas City, KS, US, 66160
US, MD Baltimore, MD, US, 21224
US, MI Ann Arbor, MI, US, 48109
US, MN Rochester, MN, US, 55905
US, MO Saint Louis, MO, US, 63156
US, NC Durham, NC, US, 27705
US, NC New Bern, NC, US, 28562
US, NC Winston-Salem, NC, US, 27104
US, NY Port Jefferson Station, NY, US, 11776
US, PA Philadelphia, PA, US, 19107
US, PA Philadelphia, PA, US, 19140
US, PA Pittsburgh, PA, US, 15213
US, PA Sayre, PA, US, 18840
US, TX Galveston, TX, US, 77555
US, VA Williamsburg, VA, US, 23188